ECOSPOR IV: An Open-Label Extension of Study SERES-012 and Open-Label Program for Evaluating SER-109 in Subjects With Recurrent Clostridioides Difficile Infection (RCDI)

Cohort 1: Subjects who had a Clostridioides difficile infection (CDI) recurrence in study SERES-012 within 8 weeks of receipt of study drug will be eligible. The purpose of this cohort is to assess safety and efficacy of SER-109 in reducing recurrence of CDI in adults who had a CDI recurrence within 8 weeks after receipt of SER-109 or Placebo in study SERES-012.
Cohort 2: Cohort 2 is an open-label program for subjects who were not part of SERES-012. The purpose of this cohort is to describe safety and tolerability of SER-109 in subjects 18 years of age or older with at least a first recurrence of CDI.

开始日期2017-10-23

申办/合作机构

Seres Therapeutics, Inc.

NCT03183128 / Completed临床3期

A Phase 3 Multicenter, RandomizeEd, Double Blind, Placebo COntrolled, Parallel Group Study to Evaluate the Safety, Tolerability, & Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium Difficile Infection (CDI) in Adults

Subjects will receive an oral dose of SER-109 in 4 capsules once daily for 3 consecutive days in Treatment Group I or matching placebo once daily for 3 consecutive days in Treatment Group II. The purpose of this study is to demonstrate the superiority of SER-109 vs placebo to reduce recurrence of CDI as determined by a toxin assay in adults up to 8 weeks after initiation of treatment.

开始日期2017-07-10

申办/合作机构

Seres Therapeutics, Inc.

NCT02437487 / Completed临床2期

ECOSPOR: A RandomizEd, Double Blind, Placebo COntrolled, Parallel Group Study of SER 109 to Prevent Recurrent ClOstRidium Difficile Infection

The study will involve administering the study drug as a single dose of study drug or placebo. This study is designed to demonstrate the superiority of the experimental drug versus placebo in adult patients with recurrent CDI.

开始日期2015-05-01

申办/合作机构

Seres Therapeutics, Inc.

[+1]

100 项与 Fecal microbiota spores, live-brpk(Seres Therapeutics) 相关的临床结果

登录后查看更多信息

100 项与 Fecal microbiota spores, live-brpk(Seres Therapeutics) 相关的转化医学

登录后查看更多信息

100 项与 Fecal microbiota spores, live-brpk(Seres Therapeutics) 相关的专利（医药）

登录后查看更多信息

项与 Fecal microbiota spores, live-brpk(Seres Therapeutics) 相关的文献（医药）

2024-04-10·Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection

Article

作者: Bryant, Jessica A ; Lodise, Thomas P ; Litcofsky, Kevin D ; Freedberg, Daniel E ; Straub, Timothy J ; Lombardo, Mary-Jane ; Ford, Christopher B ; Hasson, Brooke R ; McGovern, Barbara H ; Wortman, Jennifer R ; Diao, Liyang ; Henn, Matthew R

Abstract:

Background:

The gastrointestinal microbiota is an important line of defense against colonization with antimicrobial resistant (AR) bacteria. In this post hoc analysis of the phase 3 ECOSPOR III trial, we assessed impact of a microbiota-based oral therapeutic (fecal microbiota spores, live; VOWST Oral Spores [VOS], formerly SER-109]; Seres Therapeutics) compared with placebo, on AR gene (ARG) abundance in patients with recurrent Clostridioides difficile infection (rCDI).

Methods:

Adults with rCDI were randomized to receive VOS or placebo orally for 3 days following standard-of-care antibiotics. ARG and taxonomic profiles were generated using whole metagenomic sequencing of stool at baseline and weeks 1, 2, 8, and 24 posttreatment.

Results:

Baseline (n = 151) and serial posttreatment stool samples collected through 24 weeks (total N = 472) from 182 patients (59.9% female; mean age: 65.5 years) in ECOSPOR III as well as 68 stool samples obtained at a single time point from a healthy cohort were analyzed. Baseline ARG abundance was similar between arms and significantly elevated versus the healthy cohort. By week 1, there was a greater decline in ARG abundance in VOS versus placebo (P = .003) in association with marked decline of Proteobacteria and repletion of spore-forming Firmicutes, as compared with baseline. We observed abundance of Proteobacteria and non–spore-forming Firmicutes were associated with ARG abundance, while spore-forming Firmicutes abundance was negatively associated.

Conclusions:

This proof-of-concept analysis suggests that microbiome remodeling with Firmicutes spores may be a potential novel approach to reduce ARG colonization in the gastrointestinal tract.

2023-12-05·Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Review Article: Safety of Live Biotherapeutic Products Used for the Prevention of Clostridioides difficile Infection Recurrence

Review

作者: Garey, Kevin W ; Gonzales-Luna, Anne J ; Carlson, Travis J

Abstract:

Live biotherapeutic products (LBPs) represent a new class of therapeutics indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in adults. However, microbiota-based therapies have been used in CDI management before the Food and Drug Administration (FDA) designated this new drug class. The regulation of these microbiome-based therapies has varied, and several safety concerns have arisen over time. Requirements established by the FDA regarding the development of LBPs minimizes many of these prior concerns, and phase III trials have proven the safety and efficacy of 2 stool donor-derived LBPs: fecal microbiota, live-jslm (Rebyota™; formerly RBX2660) and fecal microbiota spores, live-brpk (Vowst™; formerly SER-109). Mild gastrointestinal side effects are common, but no severe drug-related adverse events have been reported with their use to date. A third LBP entering phase III clinical trials, VE303, follows a novel approach by sourcing bacterial strains from clonal cell banks and has demonstrated a similarly favorable safety profile.

2024-04-01·Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Update on microbiota-derived therapies for recurrent Clostridioides difficile infections

Review

作者: Davies, Kerrie ; Druart, Celine ; Kuijper, Ed ; Fitzpatrick, Fidelma ; Cordaillat-Simmons, Magali ; Benech, Nicolas ; Barbut, Frédéric ; Guery, Benoît ; Heritage, John ; Krutova, Marcela

BACKGROUND:

Faecal microbiota transplantation (FMT) is the standard treatment for patients with multiple recurrent Clostridioides difficile infection (rCDI). Recently, new commercially developed human microbiota-derived medicinal products have been evaluated and Food and Drug Administration-approved with considerable differences in terms of composition, administration, and targeted populations.

OBJECTIVES:

To review available data on the different microbiota-derived treatments at the stage of advanced clinical evaluation and research in rCDI in comparison with FMT.

SOURCES:

Phase II or III trials evaluating a microbiota-derived medicinal product to prevent rCDI.

CONTENT:

Two commercial microbiota-derived medicinal products are approved by the Food and Drug Administration: Rebyota (RBX2660 Ferring Pharmaceuticals, marketed in the United States) and VOWST (SER-109 -Seres Therapeutics, marketed in the United States), whereas VE303 (Vedanta Biosciences Inc) will be studied in phase III trial. RBX2660 and SER-109 are based on the processing of stools from healthy donors, whereas VE303 consists of a defined bacterial consortium originating from human stools and produced from clonal cell banks. All have proven efficacy to prevent rCDI compared with placebo in patients considered at high risk of recurrence. However, the heterogeneity of the inclusion criteria, and the time between each episode and CDI diagnostics makes direct comparison between trials difficult. The differences regarding the risk of recurrence between the treatment and placebo arms were lower than previously described for FMT (FMT: Δ = 50.5%; RBX2660-phase III: Δ = 13.1%; SER-109-phase III: Δ = 28%; high-dose VE303-phase-II: Δ = 31.7%). All treatments presented a good overall safety profile with mainly mild gastrointestinal symptoms.

IMPLICATIONS:

Stool-derived products and bacterial consortia need to be clearly distinguished in terms of product characterization and their associated risks with specific long-term post-marketing evaluation similar to registries used for FMT. Their place in the therapeutic strategy for patients with rCDI requires further studies to determine the most appropriate patient population and administration route to prevent rCDI.

151

项与 Fecal microbiota spores, live-brpk(Seres Therapeutics) 相关的新闻（医药）

2024-06-06

·Firstwordpharma

Seres to sell microbiome therapy Vowst to Nestlé to pay off debt

A little over a year after securing the first FDA-approved oral microbiome treatment, Seres Therapeutics is now looking to sell its flagship asset to partner Nestlé Health Science. No figures were specified in the release announcing a memorandum of understanding with Nestlé on Thursday, but Seres says the deal would "fully retire its debt" and extend its cash runway into the fourth quarter of 2025.Vowst, formerly SER-109, is an orally administered therapeutic that received FDA approval in April 2023 to prevent repeat Clostridioides difficile infections (CDI) in adults following antibacterial treatment for recurrent CDI.'Extremely successful' launchMoreno Perugini, president of medical nutrition and pharma at Nestlé Health Science, said Vowst "has been extremely successful since we first made it available to patients in June of last year… and we are pleased to continue to provide this important medication to patients."Seres reported in March that the microbiome therapy reached sales of $19.6 million in 2023 based on 1284 units sold, while the company's share of the Vowst net loss last year was $18.9 million. For the first quarter of 2024, Vowst generated revenue of $10.1 million, based on 642 units sold.Seres and Nestlé Health Science entered into a co-exclusive license agreement for the development and commercialisation of Vowst in 2021 in a deal potentially worth over $520 million. Under the new arrangement, Nestlé Health Science will acquire full ownership of the Vowst product and related intellectual property rights.Focus on SER-155"We plan to use the capital from this pending transaction to retire our existing debt facility and strengthen our balance sheet," Seres CEO Eric Shaff stated. "These actions enable [us] to enter an exciting next phase as we move SER-155 and other wholly-owned cultivated microbiome therapeutic candidates forward to important milestones."Seres expects to receive "capital infusions" from the divestiture, including an upfront payment, but did not provide specific numbers. Late last year, the company unveiled a restructuring that will hit 41% of its workforce, leading to savings of approximately $75 million to $85 million in 2024..SER-155 is currently in a Phase Ib study in patients undergoing allogeneic haematopoietic stem cell transplantation. According to Seres, the candidate could potentially reduce the incidence and severity of gastrointestinal and related bloodstream infections, as well as the risk of acute graft-versus-host disease.

临床1期引进/卖出上市批准细胞疗法

2024-06-06

·BioPharmaDive

Seres, indebted and in need of cash, agrees to sell microbiome pill to Nestle

Dive Brief:Seres Therapeutics plans to sell all the rights to its microbiome pill to Nestl Health Science as it struggles to fund operations.Under a nonbinding memorandum of understanding announced Thursday, the Swiss company will acquire all the product and intellectual property rights to Vowst, which was approved in the U.S. in 2023 to prevent the recurrence of difficult-to-treat C. diff infections. Seres expects the transaction to close within 90 days.The company didnt disclose exact financial terms for the deal, saying only that it would receive capital infusions including an upfront payment. Seres said it will use the money to retire an existing debt facility with Oaktree Capital Management and extend its cash runway into the fourth quarter of 2025.Dive Insight:The sale will allow Seres to focus on advancing SER-155 and other experimental microbiome therapies designed to fight infections. In April, the company announced it had completed patient enrollment for a Phase 1b trial of SER-155 in patients who received allogeneic hematopoietic stem cell transplants.Seres has been working with Nestl since 2016 when the companies signed a development and commercialization deal involving four medicines. In 2021, Nestl agreed to pay Seres to expand the collaboration and acquire more commercialization rights to one of those drugs, SER-109, now sold under the brand name Vowst.The pill is made from human fecal matter thats been screened and purified. Its designed to repopulate the gut with helpful bacteria to ward off infections. It was the second microbiota therapy to win Food and Drug Administration approval and the first one cleared for oral administration. But a year after the launch of Vowst, Seres is struggling. The company posted a net loss of $40.1 million in the first quarter and told investors in May that its cash was sufficient to carry operations only into the fourth quarter of this year. That was even after eliminating 41% of its workforce in a restructuring announced in November.Seres said it will enter into a service agreement with Nestl to support the transition of the product. Its new cash runway guidance is subject to performance under the service agreement. '

临床1期微生物疗法引进/卖出

2024-05-17

·生物制品圈

微生物组疗法正在兴起：新颖且发展前景广阔

近十年来，生物制药领域正兴起一种新颖的但极具发展前景的治疗方法，那就是微生物组疗法（Microbiome Therapy）。研究表明，肠道微生物占人体微生物总数的将近80%，人体肠道微生物参与人体代谢，免疫等多种人体正常功能的运行。对于肠道微生态活菌药物的研发也将大有前景。今天聚焦于肠道微生物治疗领域，呼吁中国肠道微生物组领域的公司们一起加强合作，推动这个领域一起健康持续的发展和壮大。近十年来，生物制药领域正兴起一种新颖的但极具发展前景的治疗方法，那就是微生物组疗法（Microbiome Therapy）。各种研究显示人体健康与微生物组有着密切的关系，人体内的微生物是人体不可或缺的重要组成部分。人体肠道微生物基因数量是人体基因数量的100倍以上，人体肠道微生物参与人体代谢，免疫等多种人体正常功能的运行。研究表明，肠道微生物占人体微生物总数的将近80%。目前研究发现，肠道菌群紊乱会引起多种肠道和肠道外疾病，如炎症性肠病(IBD）、肠易激综合症（IBS）、肥胖（Obesity）、代谢综合症（Metabolic syndrome）、中枢神经系统疾病（CNS）、自身免疫系统疾病（Autoimmune diseases）、肿瘤(Tumor）等。尽管在某些疾病中已经发现肠道菌群会发生特异性的改变(某些严重的肠道疾病、肿瘤和肥胖），但由于肠道菌群的多样性及其他微生物、化学物质的存在，很难在疾病和特异性菌群改变之间建立明确的因果关系。不过基于对“肠道菌群紊乱在疾病发生中作用”的认识，医生们产生了用健康人肠道细菌来治疗人类疾病的想法。 1958年，美国Ben Eiseman医生及其同事首次用健康人的粪便成功治愈了四例严重的伪膜性肠炎患者，开启了现代医学关于粪菌移植（Fecal microbiota transplantation，FMT）的征程。正常人体粪菌中包括近1000多种细菌，粪菌移植的原理就是将原来已损害的肠道屏障通过细菌移植而达到修复作用。随着全世界对FMT的重视，它将会得到更为迅速的发展。近年来，Petrof等从健康人粪便分离出的33种细菌，培养后制成细菌混合物，利用常规FMT途径成功治愈两例RCDI患者，揭示用人工组合菌群治疗（Synthetic microbiota transplantation，SMT）代替FMT的可能性。如果可以通过人工培养特定的细菌，并组合成最佳比例和数量级的菌群，实现标准化SMT，不但可以确保细菌来源的安全性和可控性、进行有效质控、减少供体筛查环节，同时还可以将人工合成的细菌做成冻干粉或胶囊，以处方药的形式直接口服或经内镜直接输入肠道进行治疗。因此，SMT将是FMT或者肠道菌群干预治疗的重要发展方向。基于FMT的疗效，带给科学家的启示和肠道菌群宏基因组的研究，发现和开发新的菌群干预靶标或途径，是一个重要的新技术转化领域。成立于2017年的奕景生物科技（Intuition Biosciences）是中国较早专注于肠道微生态活菌药物研发的公司之一。目前，肠道微生态活菌药物（Live biotherapeutic products，LBP）可分为粪菌移植、单一菌株活菌药物，及多菌株活菌药物。奕景生物开发的是多菌株口服胶囊药物，更关注在微生态系统（Microbiome Ecosystem Therapeutics，MET）的功能的建立，从而发挥各菌株间的协同效应，它的整个工艺制备过程包括：通过对于特别的健康供体的粪便中指定菌株进行逐个分离、纯化、培养、放大生产，直到冻干后再以一定比例进行菌株混合，装入胶囊成药。 MET与FMT最大的不同就是不需要每一次都要新的供体，一旦提取了一次菌株，逐个制备成菌种库（Strain bank）以后，就能不断放大。因此，正如之前所提到的，MET的安全性和品质比FMT都能够得到更加精准地把控，而且能够真正实现成药性和工业化量产。然而，伴随的难点就是如何定义哪些是有益菌、哪些是无用的，如何确保这些菌株的配比能在人体内正常释放等。所以在做临床的同时，很多精力投入到了CMC工艺上来克服这些困难。奕景生物的核心技术能力目前已经能做到： 1、创建了一个确定的复杂的微生物群落，包括难以培养的厌氧菌； 2、拥有微生物生态系统开发的完整技术平台和多个方面的智能财产权； 3、能够开发多代产品，以治疗不同的疾病； 4、能够在更多的研究数据出现时调整供体和细菌组成； 5、用于不同微生物制剂和生长条件的体外功能性测试（例如，营养、药物、去恒化器）与纯粹的基因组检测相对比； 6、恰当使用代谢组学来定义和测试生态系统； 7、伴随诊断平台作为质控过程及住院患者的试验/登记的一部分。一个健康的中国人的微生物组一定和生活在美国和欧洲的人有着显着的差异。因此，我们必须要针对中国病人的情况量身定制微生物组治疗方案，这点非常重要。故此，奕景生物的主旨之一就是将这些顶尖技术和产品带入中国并在中国建立全球生产研发、生产平台，为国际市场提供临床及商业产品。肠道微生物治疗领域真正在中国起步的时候，基因检测行业已经兴起并逐渐成熟了，无论从16RNS还是到Metagenomics，从公司到医院，都具备了一定的检测能力。这对于肠道微生物产业的发展是一个巨大的利好消息，只有上下游的打通才能够让患者尽早受益。虽然中国肠道微生物治疗领域属于起步阶段，但是我们相信在国外Seres公司临床III期SER-109的CDI利好的数据出来后，中国的产业发展也会加大步伐。内容来源于网络，如有侵权，请联系删除。

微生物疗法临床研究

100 项与 Fecal microbiota spores, live-brpk(Seres Therapeutics) 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
艰难梭菌感染	美国	Seres Therapeutics, Inc.	2023-04-26

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性艰难梭菌感染	临床3期	美国	Seres Therapeutics, Inc.	2017-10-23
复发性艰难梭菌感染	临床3期	加拿大	Seres Therapeutics, Inc.	2017-10-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03183128 (CTgov)	临床3期	艰难梭菌感染	182	SER-109 (SER-109)	淵窪觸憲鑰廠鹹獵築鬱(衊齋構觸觸夢鑰繭夢餘) = 選鏇憲膚糧製壓襯觸鹹遞網網衊鹹繭艱鬱鏇夢 (廠齋壓夢網鬱膚鏇獵遞, 範構鑰積艱鹽齋膚壓鏇 ~ 構築鹽獵蓋糧選憲夢鹹) 更多	-	2023-04-27
				Placebo (Placebo)	淵窪觸憲鑰廠鹹獵築鬱(衊齋構觸觸夢鑰繭夢餘) = 願鬱淵遞醖鏇壓夢顧鹹遞網網衊鹹繭艱鬱鏇夢 (廠齋壓夢網鬱膚鏇獵遞, 製襯築積衊壓齋鑰鹹艱 ~ 醖衊願襯夢膚憲鬱淵鑰) 更多
NCT03183128 (FDA) 人工标引	临床3期	艰难梭菌感染	182	VOWST	遞醖簾願鹽夢願鏇淵艱(製鬱觸淵顧膚餘遞築構) = 襯齋廠製淵願積壓獵衊鏇壓遞夢鑰艱壓醖廠構 (廠憲觸糧壓繭網鹽鑰觸 ) 更多	积极	2023-04-26
				Placebo	遞醖簾願鹽夢願鏇淵艱(製鬱觸淵顧膚餘遞築構) = 願憲鹽鹽鏇獵觸繭鏇糧鏇壓遞夢鑰艱壓醖廠構 (廠憲觸糧壓繭網鹽鑰觸 ) 更多
NCT03183141 (CTgov)	临床3期	艰难梭菌感染 \| 复发性艰难梭菌感染	263	SER-109 (Cohort 1)	窪鑰積蓋製蓋構鹹顧積(繭鬱襯糧艱製襯醖齋窪) = 網廠構範醖憲廠簾顧鏇觸選廠選鏇選遞積衊獵 (積製網鏇壓鑰鹹築築夢, 艱鹽簾選壓繭餘鬱選齋 ~ 餘齋壓廠選鹽遞淵鑰繭) 更多	-	2023-03-31
				SER-109 (Cohort 2)	窪鑰積蓋製蓋構鹹顧積(繭鬱襯糧艱製襯醖齋窪) = 構廠鏇製願醖顧淵鬱製觸選廠選鏇選遞積衊獵 (積製網鏇壓鑰鹹築築夢, 壓窪獵膚糧齋網憲簾衊 ~ 蓋蓋築淵膚艱鹹網繭觸) 更多
NCT03183141 (ECOSPOR IV, Pubmed)	临床3期	艰难梭菌感染	263	SER-109	鏇築積餘鬱衊顧餘網衊(齋簾糧願築鏇鑰壓範鏇) = 鹽夢積廠鹹遞範顧膚窪願簾憲網構選遞鬱廠壓 (製艱觸鑰鹹觸範構獵觸, 5.6% ~ 12.8%)	-	2023-02-01
NCT03183128 (ECOSPOR III, ASCO2022) 人工标引	临床3期	艰难梭菌感染	182	SER-109	構鏇願簾鬱網構窪簾簾(構範窪選膚蓋廠鏇範積) = 網膚餘衊獵簾壓窪鏇簾獵醖窪選鬱艱願糧廠糧 (壓獵廠觸製網網獵鏇鏇 ) 更多	积极	2022-06-02
				placebo	構鏇願簾鬱網構窪簾簾(構範窪選膚蓋廠鏇範積) = 鬱窪遞觸繭築觸醖願繭獵醖窪選鬱艱願糧廠糧 (壓獵廠觸製網網獵鏇鏇 ) 更多
NCT03183128 (ECOSPOR III, Pubmed) 人工标引	临床3期	艰难梭菌感染	182	Ser-109	憲憲積衊顧築齋顧鏇壓(膚鬱獵齋獵蓋廠艱窪襯) = 築壓繭廠蓋積獵糧膚夢築壓築製憲顧鏇淵鬱蓋 (蓋製夢憲衊鬱製蓋齋餘 )	积极	2022-01-20
				Placebo	憲憲積衊顧築齋顧鏇壓(膚鬱獵齋獵蓋廠艱窪襯) = 糧遞衊鑰獵襯選範窪顧築壓築製憲顧鏇淵鬱蓋 (蓋製夢憲衊鬱製蓋齋餘 )
NCT02437487 (Pubmed \| Clin Infect Dis) 人工标引	临床2期	艰难梭菌感染	89	SER-109	膚製築鏇遞鬱憲簾蓋鹽(醖鹹醖鹽選製範觸餘窪) = 願窪遞衊鏇鏇憲顧繭夢願淵製鏇艱窪網鏇鏇壓 (窪餘簾鹽觸鑰窪廠齋鑰 ) 更多	积极	2021-06-15
				Placebo	膚製築鏇遞鬱憲簾蓋鹽(醖鹹醖鹽選製範觸餘窪) = 壓簾簾築壓艱齋餘願觸願淵製鏇艱窪網鏇鏇壓 (窪餘簾鹽觸鑰窪廠齋鑰 ) 更多
NCT02437487 (CTgov)	临床2期	艰难梭菌感染	89	SER-109 (SER-109)	願製蓋衊遞鬱艱鏇夢壓(築壓膚鹽鏇簾衊鬱壓蓋) = 鏇獵鏇遞願壓夢築範窪繭衊觸網鑰鹹遞鏇選選 (製鏇顧築衊選積網夢築, 憲鹹艱餘遞衊繭鏇鹹繭 ~ 構餘鹹繭廠鑰獵觸簾鹽) 更多	-	2018-07-26
				Placebo (Placebo)	願製蓋衊遞鬱艱鏇夢壓(築壓膚鹽鏇簾衊鬱壓蓋) = 顧構遞蓋醖膚鹽鑰願遞繭衊觸網鑰鹹遞鏇選選 (製鏇顧築衊選積網夢築, 鹹顧鏇壓窪構淵蓋鹹醖 ~ 廠積獵選憲襯積鹽製選) 更多